Dren Bio

Dren Bio is a South San Francisco-based biotech founded in 2019, advancing a pipeline of first-in-class antibody therapeutics. The company's core approach involves engineering antibodies to selectively engage immune effector cells, like macrophages, to phagocytose and clear pathological targets. With two clinical-stage programs and a broader preclinical portfolio in oncology, immunology, and neurology, Dren aims to address significant unmet medical needs through its novel depletion mechanisms. As a private, pre-revenue company, its success hinges on clinical validation of its proprietary platforms.

Proprietary Targeted Myeloid Engager and Phagocytosis Platform designed to engineer antibodies that engage macrophages to phagocytose and deplete specific pathogenic cells or aggregates.

Dren operates in highly competitive spaces (oncology/autoimmunity) but differentiates via its focus on myeloid cell engagement for phagocytosis, a less crowded approach than T-cell engagers or broad immunosuppressants. Competitors include companies developing other cell-depleting therapies (e.g., CD38, BCMA targeting) and broader immuno-oncology players.